Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
- PMID: 32914712
- DOI: 10.2174/1389450121666200910160404
Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
Abstract
Bone is one of the dynamic tissues in the human body that undergoes continuous remodelling through subsequent actions of bone cells, osteoclasts, and osteoblasts. Several signal transduction pathways are involved in the transition of mesenchymal stem cells into osteoblasts. These primarily include Runx2, ATF4, Wnt signaling and sympathetic signalling. The differentiation of osteoclasts is controlled by M-CSF, RANKL, and costimulatory signalling. It is well known that bone remodelling is regulated through receptor activator of nuclear factor-kappa B ligand followed by binding to RANK, which eventually induces the differentiation of osteoclasts. The resorbing osteoclasts secrete TRAP, cathepsin K, MMP-9 and gelatinase to digest the proteinaceous matrix of type I collagen and form a saucer-shaped lacuna along with resorption tunnels in the trabecular bone. Osteoblasts secrete a soluble decoy receptor, osteoprotegerin that prevents the binding of RANK/RANKL and thus moderating osteoclastogenesis. Moreover, bone homeostasis is also regulated by several growth factors like, cytokines, calciotropic hormones, parathyroid hormone and sex steroids. The current review presents a correlation of the probable molecular targets underlying the regulation of bone mass and the role of essential metabolic elements in bone remodelling. Targeting these signaling pathways may help to design newer therapies for treating bone diseases.
Keywords: Bone; RANK; estrogen; molecular signaling; osteoblast; osteoclast.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand.Bone. 1999 Nov;25(5):517-23. doi: 10.1016/s8756-3282(99)00210-0. Bone. 1999. PMID: 10574571
-
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.Medscape Womens Health. 2000 Mar;5(2):5. Medscape Womens Health. 2000. PMID: 10792853 Review.
-
Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.Osteoporos Int. 2000;11(11):905-13. doi: 10.1007/s001980070028. Osteoporos Int. 2000. PMID: 11193242 Review.
-
Regulatory mechanisms of osteoblast and osteoclast differentiation.Oral Dis. 2002 May;8(3):147-59. doi: 10.1034/j.1601-0825.2002.01829.x. Oral Dis. 2002. PMID: 12108759 Review.
-
Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.Endocrinology. 2005 Apr;146(4):1991-8. doi: 10.1210/en.2004-1167. Epub 2004 Dec 23. Endocrinology. 2005. PMID: 15618359
Cited by
-
A review of mathematical modeling of bone remodeling from a systems biology perspective.Front Syst Biol. 2024;4:1368555. doi: 10.3389/fsysb.2024.1368555. Epub 2024 Apr 8. Front Syst Biol. 2024. PMID: 40012834 Free PMC article.
-
Engineered Metal-Organic Frameworks for Targeted CRISPR/Cas9 Gene Editing.ACS Pharmacol Transl Sci. 2025 Mar 12;8(4):1028-1049. doi: 10.1021/acsptsci.5c00047. eCollection 2025 Apr 11. ACS Pharmacol Transl Sci. 2025. PMID: 40242591 Review.
-
Exploring the Potential of Moringa oleifera in Managing Bone Loss: Insights from Preclinical Studies.Int J Med Sci. 2025 Jan 21;22(4):819-833. doi: 10.7150/ijms.103241. eCollection 2025. Int J Med Sci. 2025. PMID: 39991771 Free PMC article. Review.
-
Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway.Front Oncol. 2021 Feb 15;10:615146. doi: 10.3389/fonc.2020.615146. eCollection 2020. Front Oncol. 2021. PMID: 33659212 Free PMC article.
-
A Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases.Int J Mol Sci. 2022 Jul 30;23(15):8468. doi: 10.3390/ijms23158468. Int J Mol Sci. 2022. PMID: 35955603 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous